Literature DB >> 10204697

Multicenter evaluation of a new rapid automated human immunodeficiency virus antigen detection assay.

B Weber1, A Mühlbacher, U Michl, G Paggi, V Bossi, C Sargento, R Camacho, E H Fall, A Berger, U Schmitt, W Melchior.   

Abstract

Although human immunodeficiency virus (HIV) antigen assays are of limited value for monitoring antiretroviral therapy, they play an important role for confirmatory testing of fourth generation HIV screening enzyme immunoassay (EIA) reactive samples. In a multicenter study, a new automated rapid p24 antigen assay, Elecsys HIV Ag (Roche Diagnostics Boehringer Mannheim GmbH, Penzberg, Germany), was compared to FDA licensed tests (Abbott HIV-1 Ag monoclonal and Coulter HIV-1 p24 antigen assay). In the evaluation 27 seroconversion panels were included, sera from the acute phase of infection, single and follow-up samples from HIV antibody positive patients, dilution series of HIV antigen positive standards, sera and cell culture supernatants infected with different HIV-1 subtypes (A-H, and O) HIV-2 and recombinant HIV-1 (gag/env) isolates. To challenge the specificity of the new assay, 2565 unselected blood donors, sera from pregnant women, dialysis and hospitalized patients and 407 potentially cross-reactive samples were investigated. Acute HIV infection was detected in three to eight seroconversion panels earlier with Elecsys HIV Ag than with the alternative assays. Higher numbers of serum samples from HIV infected patients tested positive by Elecsys HIV Ag than with the comparative assays. All HIV-1 subtypes and HIV-2 isolates were recognized with Elecsys HIV Ag. Abbott HIV-1 Ag monoclonal and Coulter HIV-1 p24 antigen assay showed a variable sensitivity for the different HIV-1 subtypes. The specificity of Elecsys HIV Ag and Coulter HIV-1 p24 antigen assay were 99.8 and 99.93%, respectively. All the eight sera that were false reactive by Elecsys HIV Ag were tested negative with the Elecsys HIV Ag Neutralization Test. In conclusion, Elecsys HIV Ag was more sensitive than the alternative assays and showed a high specificity in combination with the neutralization assay. The very short incubation time of 18 min and the fully automated procedure of Elecsys HIV Ag which permits direct testing from the primary patient blood collection tube, represent a major improvement for routine laboratory diagnosis in comparison to the alternative assays.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204697     DOI: 10.1016/s0166-0934(98)00162-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Contribution of combined detection assays of p24 antigen and anti-human immunodeficiency virus (HIV) antibodies in diagnosis of primary HIV infection by routine testing.

Authors:  T D Ly; C Edlinger; A Vabret
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity.

Authors:  Bernard Weber; Lutz Gürtler; Rigmor Thorstensson; Ulrike Michl; Annelies Mühlbacher; Philippe Bürgisser; Roberto Villaescusa; Adolfo Eiras; Christian Gabriel; Herbert Stekel; Srivilai Tanprasert; Sinenaart Oota; Maria-Jose Silvestre; Cristina Marques; Maria Ladeira; Holger Rabenau; Annemarie Berger; Urban Schmitt; Walter Melchior
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra.

Authors:  Bernard Weber; Annemarie Berger; Holger Rabenau; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

4.  Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.

Authors:  Mark W Pandori; John Hackett; Brian Louie; Ana Vallari; Teri Dowling; Sally Liska; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

5.  False-positive human immunodeficiency virus antibody test in a dialysis patient.

Authors:  Douglas M Silverstein; Diego H Aviles; V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.